BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32473488)

  • 1. High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era.
    Mozas P; Rivas-Delgado A; Rivero A; Dlouhy I; Nadeu F; Balagué O; González-Farré B; Baumann T; Giné E; Delgado J; Villamor N; Campo E; Pérez-Galán P; Filella X; Magnano L; López-Guillermo A
    Leuk Res; 2020 Jul; 94():106371. PubMed ID: 32473488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
    Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
    Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
    Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
    Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
    Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
    Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
    Umino K; Fujiwara SI; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Lymphoma; 2017 Feb; 58(2):316-323. PubMed ID: 27267694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.
    Mir MA; Maurer MJ; Ziesmer SC; Slager SL; Habermann T; Macon WR; Link BK; Syrbu S; Witzig T; Friedberg JW; Press O; LeBlanc M; Cerhan JR; Novak A; Ansell SM
    Blood; 2015 Feb; 125(6):992-8. PubMed ID: 25422100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
    Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
    Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
    Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
    Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.
    Evereklioglu C; Er H; Türköz Y; Cekmen M
    Mediators Inflamm; 2002 Apr; 11(2):87-93. PubMed ID: 12061429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
    Yoshizato T; Nannya Y; Imai Y; Ichikawa M; Kurokawa M
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):410-6. PubMed ID: 23747081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.
    Paradisi R; Vicenti R; Macciocca M; Seracchioli R; Rossi S; Fabbri R
    Fertil Steril; 2016 Oct; 106(5):1176-1182. PubMed ID: 27430206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis.
    Bal A; Unlu E; Bahar G; Aydog E; Eksioglu E; Yorgancioglu R
    Clin Rheumatol; 2007 Feb; 26(2):211-5. PubMed ID: 16583185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
    Marri PR; Hodge LS; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Cerhan JR; Novak AJ; Ansell SM
    Clin Cancer Res; 2013 Dec; 19(24):6812-9. PubMed ID: 24141626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.
    Rutkowski P; Kaminska J; Kowalska M; Ruka W; Steffen J
    Int J Cancer; 2002 Aug; 100(4):463-71. PubMed ID: 12115531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
    Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
    Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
    Erbağci AB; Herken H; Köylüoglu O; Yilmaz N; Tarakçioglu M
    Mediators Inflamm; 2001 Jun; 10(3):109-15. PubMed ID: 11545247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.
    Raziuddin S; Sheikha A; Abu-Eshy S; al-Janadi M
    Cancer; 1994 May; 73(9):2426-31. PubMed ID: 8168046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.